With a long-running securities fraud class action against Pfizer over the drugs Celebrex and Bextra finally lurching toward trial, both Pfizer's lawyers at Simpson Thacher and DLA and their opposing counsel at Grant & Eisenhofer have lost bids for adverse inference rulings based on alleged misconduct.

Appearances Plaintiffs' Lead Counsel for Consolidated Securities Class Action: By: Donald R. Hall, Jr., Esq., Frederic Scott Fox, Esq., Robert N. Kaplan, Esq., Kaplan Fox & Kils

Justice Bernard J. Fried NEW YORK COUNTY Supreme Court Appearances: For Plaintiff: (Robert Gold, Joseph G. Finnerty III) DLA Piper US LLP

For close to two years, counsel for Bank of America at Cleary Gottlieb and Wachtell Lipton have been struggling--and largely failing--to tame consolidated securities, ERISA, and derivative litigation over BofA's 2008 merger with Merrill Lynch. Will Brad Karp, Ted Wells, and their partners at Paul Weiss fare any better?

U.S. DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK For Plaintiffs: Stuart M. Grant, James J. Sabella, Megan D. McIntyre, Jeff A. Almeida, Christine M. Mackintosh, and Jill Agro, Gr

Andrias, J.P., Saxe, Nardelli, Sweeny, McGuire, JJ. 9741 Index 604479/01 Landau, P.C., successor, by change of name to Morris J. Eisen, P.C., et al., Plaintiffs-Appe

Cite as: Carl v. Griffin, 08 Civ. 4981, NYLJ 1202484847107, at *1 (SDNY, Decided March 2, 2011)District Judge Richard M. BermanDecided: M